Evidence for increased endogenous dopaminergic inhibition of aldosterone secretion in prolactinoma

Aldosterone responsiveness to consecutive i.v. injections of metoclopramide 1 mg, 2.5 mg and 10 mg was studied in 8 patients with prolactinoma and normally preserved adrenal function and in 14 healthy volunteers. In the patients, aldosterone response to metoclopramide 1 mg was blunted. After metoclo...

Full description

Saved in:
Bibliographic Details
Published inHormone and metabolic research Vol. 18; no. 10; p. 704
Main Authors Jungmann, E, Schwedes, U, Althoff, P H, Rosak, C, Schöffling, K
Format Journal Article
LanguageEnglish
Published Germany 01.10.1986
Subjects
Adult
Aldosterone - secretion
Dopamine - physiology
Female
Humans
Male
Metoclopramide - pharmacology
Middle Aged
Pituitary Neoplasms - secretion
Prolactin - secretion
Online AccessGet more information

Cover

More Information
Summary:Aldosterone responsiveness to consecutive i.v. injections of metoclopramide 1 mg, 2.5 mg and 10 mg was studied in 8 patients with prolactinoma and normally preserved adrenal function and in 14 healthy volunteers. In the patients, aldosterone response to metoclopramide 1 mg was blunted. After metoclopramide 10 mg, aldosterone rose to the same levels in patients and volunteers. In the patients, however, percentage rise of aldosterone was enhanced, since the appropriate base line concentration of aldosterone was decreased. Thus, there is evidence for increased endogenous dopaminergic inhibition of aldosterone secretion in prolactinoma.
ISSN:0018-5043
DOI:10.1055/s-2007-1012411